COF
48
3
MPC
28
3
HSY
32
3
LEG
16
2
XEL
48
11
DIS
70
2
PSA
43
6
O
26
16
APH
53
3
HPQ
55
3
PNR
56
2
HBI
53
4
EA
41
3
LH
33
3
ORCL
49
3
BMY
40
-5
USB
50
3
MET
58
2
MAR
57
3
NOV
45
2
COF
48
3
MPC
28
3
HSY
32
3
LEG
16
2
XEL
48
11
DIS
70
2
PSA
43
6
O
26
16
APH
53
3
HPQ
55
3
PNR
56
2
HBI
53
4
EA
41
3
LH
33
3
ORCL
49
3
BMY
40
-5
USB
50
3
MET
58
2
MAR
57
3
NOV
45
2
Financhill
Back

Monte Rosa Therapeutics 10K Form

Sell
21

GLUE
Monte Rosa Therapeutics

Last Price:
$6.92
Seasonality Move:
-3.94%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive GLUE News And Ratings

See the #1 stock for the next 7 days that we like better than GLUE

GLUE Financial Statistics

Sales & Book Value

Annual Sales: --
Cash Flow: $-21.4M
Price / Cash Flow: 0
Annual Sales: $3.35
Price / Book: 2.07

Profitability

EPS (TTM): -1.83000
Net Income (TTM): $-119.4M
Gross Margin: --
Return on Equity: 0%
Return on Assets: 0%

Monte Rosa Therapeutics Earnings Forecast

Key Monte Rosa Therapeutics Financial Ratios

  • The Interest Expense is -0.01% of Operating Income.
  • Per Share Earnings over the last 5 years have been positive in 1 years.

Monte Rosa Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: GLUE
Website: monterosatx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 6.03
Quick Ratio: 5.83

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

GLUE Technical Analysis vs Fundamental Analysis

Sell
21
Monte Rosa Therapeutics (GLUE) is a Sell

Is Monte Rosa Therapeutics a Buy or a Sell?